Share price speculation thanks to drones and artificial intelligence: Rheinmetall, BioNTech, and NetraMark shares

NetraMark Holdings: Low-cost AI specialist with takeover potential

NetraMark Holdings is positioning itself at the interface between the pharmaceutical industry and artificial intelligence – aiming to make clinical trials more efficient, precise, and compliant with regulations through AI-supported analytics.

A new scientific publication in the Journal of the Society for Clinical Data Management (JSCDM) shows that the technology company is well on its way to establishing itself as one of the designers of the next generation of clinical trials. The lead author of "Current Opportunities for the Integration and Use of AI/ML in Clinical Trials: Perspectives on Good Clinical Practice" is Dr. Joseph Geraci, Founder and Chief Scientific Officer of NetraMark. The publication is based on collaboration with renowned representatives of leading pharmaceutical companies and health authorities, including Pfizer, Sanofi, the FDA (US), EMA (EU), and technology companies such as Cognizant and Saama Technologies. The common message: Artificial intelligence and machine learning (ML) have the potential to improve data quality and patient outcomes in clinical research significantly.

Specifically, the paper examines seven practical use cases where AI has been shown to deliver benefits in terms of transparency, safety, efficiency, and accuracy in clinical trials. The scenarios range from patient stratification and data validation to the prediction of treatment outcomes.

Of course, NetraAI is also mentioned. AI is at the heart of NetraMark's technology platform, which is specifically designed to address the challenges of small, fragmented, or difficult-to-interpret data sets - a common problem in early clinical phases or for rare diseases. The platform enables pharmaceutical companies to identify potential patient groups more accurately, detect anomalies at an early stage, and optimize clinical designs – all while taking regulatory requirements into account. NetraMark has already gained an important partner for the market penetration of NetraAI in the current year. The contract research organization Worldwide Clinical Trials (Worldwide) offers its customers the NetraAI platform to optimize studies, achieve shorter timelines, lower costs, and ultimately achieve higher success rates.

NetraMark shares have been trading sideways since February. The Company is currently valued at around CAD 100 million for its AI business. This is unlikely to remain the case for long.

https://youtu.be/asqAzE7_2-M?si=7gsnEPeZxIm5VI4s

BioNTech focuses on AI

Could NetraMark be a takeover candidate for BioNTech? Perhaps. What is certain is that the Mainz-based company has been using its billions in revenue from the COVID-19 vaccine for several years to establish itself as a pioneer in the field of artificial intelligence (AI) in drug research.

BioNTech primarily uses AI to identify new targets, predict drug candidates, and individualize cancer therapies. In personalized oncology - a core focus of the Company - AI enables the rapid analysis of large amounts of data from individual patient tumor profiles. The goal is to develop customized mRNA-based therapies that mobilize the immune system to target cancer cells. According to the Company, AI can reduce the time needed to identify potential mRNA candidates from several months to a few days or weeks. BioNTech can also respond more quickly to new pathogens – a decisive advantage in pandemic situations or with rapidly mutating cancers.

In order to systematically expand its AI expertise, BioNTech has made targeted acquisitions of companies in the field of artificial intelligence in recent years. Probably the most important AI acquisition to date was the takeover of the British start-up InstaDeep for around GBP 500 million in 2023. InstaDeep specializes in deep reinforcement learning and bioinformatics. The Company's AI models help solve complex biological problems like protein structure prediction, vaccine design, and drug screening. Since the acquisition, InstaDeep has been an integral part of the research platform as BioNTech AI Solutions.

BioNTech has announced that it will continue to actively pursue acquisitions in the AI sector. This will primarily focus on areas such as generative AI for molecular design, image analysis in pathology, and multi-omics data integration.

Rheinmetall: Drones for Europe

Rheinmetall is also focusing on high-tech. Although Germany's largest defense contractor is best known for its tanks, howitzers, and ammunition, it is continuing to expand its portfolio, particularly in the technology sector. Yesterday, it attracted attention with a strategic partnership in the drone sector. Rheinmetall plans to work with US technology company Anduril Industries to jointly develop and manufacture various software-defined autonomous systems.

Among other things, the partnership will focus on European variants of Anduril's Barracuda drone and Fury kamikaze drone, as well as their integration into Rheinmetall's Battlesuite digital platform for networked military systems. In addition, opportunities in the European market for solid-propellant rocket engines will be explored.

Anduril CEO Brian Schimpf commented: "Together with Rheinmetall, we are developing systems that can be produced quickly, deployed widely, and adapted to changing NATO missions."

This shows once again that Rheinmetall is increasingly focusing on cooperation in order to rapidly expand its product portfolio and deliver quickly. At the end of April, for example, an agreement was reached with Lockheed Martin to manufacture ATACMS missiles and parts for the F-35 fighter jet in Europe. There are also plans to establish a European center of excellence for rockets and missiles.

AI has the potential to revolutionize drug research. NetraMark is an exciting AI stock with catch-up potential. It will also likely become an increasingly attractive takeover target, perhaps for BioNTech. The Mainz-based company is also strongly committed to AI. Rheinmetall also wants to play a role in future technologies. To deliver quickly, it is entering into partnerships, which should pay off.